This concept of TAFIa inhibition, leading to a profibrinolytic effect without compromising the strongly intertwined anti-inflammatory role, might therefore be of interest for the development of TAFI inhibitors to treat thrombotic diseases. Here, CPB2 is linked to thrombotic disease.